Efficacy and safety outcomes in patients with relapsing forms of MS treated with the CNS-Penetrating BTK inhibitor SAR442168: results from the phase 2b trial

D. S. Reich, W. D. Honeycutt,C. Laganke,D. -A. Laplaud,X. Montalban,D. Robertson, B. M. J. Uitdehaag,S. Wray,D. Wynn,A. Matta, T. Turner,E. Wallstrom, X. Zhang, A. Traboulsee

EUROPEAN JOURNAL OF NEUROLOGY(2020)

Cited 4|Views5
No score
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined